Head-to-head · WeighScore
AM Rx vs Direct Meds
The verdict
Direct Meds takes it — 82.6/100 to 49.9/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Direct Meds |
|---|---|---|
| WeighScore | 49.9/100 | 82.6/100 |
| Grade | C | B− |
| Scorecard rank | #490 | #19 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | $179/mo |
| Tirzepatide | Not disclosed | $224/mo |
| Coverage | Coverage not published | Not publicly listed |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #490 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #19 · B−
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.